Compare ACR & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACR | ANTX |
|---|---|---|
| Founded | 2005 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 146.1M | 172.9M |
| IPO Year | 2005 | 2022 |
| Metric | ACR | ANTX |
|---|---|---|
| Price | $12.55 | $4.86 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $24.50 | $2.00 |
| AVG Volume (30 Days) | 31.6K | ★ 189.9K |
| Earning Date | 04-30-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.56 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $79,946,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.57 | $1.00 |
| 52 Week High | $24.61 | $7.19 |
| Indicator | ACR | ANTX |
|---|---|---|
| Relative Strength Index (RSI) | 31.56 | 33.25 |
| Support Level | N/A | $4.55 |
| Resistance Level | $14.97 | $5.21 |
| Average True Range (ATR) | 0.53 | 0.36 |
| MACD | -0.02 | -0.11 |
| Stochastic Oscillator | 17.59 | 5.33 |
ACRES Commercial Realty Corp is a commercial real estate investment trust that focuses on originating, holding, and managing commercial real estate (CRE) mortgage loans and equity investments in commercial real estate properties through direct ownership and joint ventures. The company invests in commercial real-estate-related assets, including whole loans, A notes, B notes, mezzanine loans, and mortgage-related securities, as well as commercial finance assets, which include other asset-backed securities, senior secured corporate loans, equipment leases and notes, trust preferred securities, debt tranches of collateralized debt obligations, and private equity investments mainly issued by financial institutions.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.